期刊文献+

样本库受试者隐私保护管理的现状分析 被引量:4

Status Analysis of Subjects' Privacy Protection Management in Sample Bank
下载PDF
导出
摘要 总结了国内外样本库隐私保护方面的法规和指南,分析了国内样本库隐私保护方面的受试者是否从真正意义上"去标识化"和隐私是否会被泄露等问题。在此基础上,结合我国国情提出相应的建议,以期通过建立完善的去标识化流程,加强访问权限以及生物样本库系统的监管,并加强对研究者隐私规则的培训,加强相关监督和质控管理等措施改善目前的状况。 This paper summarized the domestic and foreign laws and guidelines of privacy protection in sample bank and analyzed the problems that whether the subjects were in the real sense of "no identification" and whether the privacy would be leaked. Based on this and combined with Chinese conditions, it put forward the corresponding suggestions to improve the current situation, through establishing a thorough process of no identification, strengthening the access permission and the supervision of biological sample bank system, strengthening the training of researchers' privacy rules ,strengthening the related supervision and management of quality control, and so on.
作者 陈晓云 王思洁 高洁 姜维洁 CHEN Xiaoyun WANG Sifie GAO Jie JIANG Weifie(Ethics Committee, the Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200126, China The Experiment Center, the Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200126, China)
出处 《中国医学伦理学》 2017年第1期74-77,共4页 Chinese Medical Ethics
基金 上海市卫计委中医药新三年行动计划助项目。编号:ZY3-RCPY-3-1058 ZY3-CCCX-2-1002 Fogarty International Center of the US NIH(美国国立卫生研究院基金(NIH))
关键词 生物样本库 隐私保护 医学临床科研 科研伦理 Biological Sample Bank Privacy Protection Medical Clinical Research Research Ethics
  • 相关文献

参考文献9

二级参考文献132

  • 1周乙华,庄辉.实验室感染与生物安全[J].中华预防医学杂志,2005,39(3):215-217. 被引量:65
  • 2季加孚.北京大学临床肿瘤学院标本库的建设[J].北京大学学报(医学版),2005,37(3):329-330. 被引量:80
  • 3朱彤,李成毅,江朝强,TH Lam,K K Cheng.广州队列研究生物库中条形码技术应用与评价[J].中国公共卫生,2006,22(9):1097-1098. 被引量:6
  • 4孙磊.美国组织库事业发展情况[J].中国修复重建外科杂志,2006,20(11):1145-1146. 被引量:13
  • 5US Department of Health and Human Services, Food and Drug Administration. Challenge and opportunity on the critical path to new medical products [ EB/OL]. (2004-03-16). http://www. fda. gov/ScienceResearch/SpecialTopics/CriticalPathIntiative/Cri- ticalPathOpportunitiesReports/. UCM0771262. htm.
  • 6US Department of Health and Human Services, Food and Drug Administration. Critical path opportunities report [ EB/OL ]. (2006-03). http ://www. fda. gov/ScienceResearch/SpecialTopics/ CriticalPathIntiative/CriticalPathOpportunitiesReports/. UCM077- 254. pdf.
  • 7Vaught J, Rogers J, Myers K, et al. An NCI perspective on creating sustainable biospecimen resources. J Natl Cancer Inst Monogr, 2011,42:1-7.
  • 8Vgv6ri , Welinder C, Lindberg H, et al. Biobank resources for future patient care:developments, principles and concepts. J Clin Bioinforma, 2011,1:24.
  • 9Merrero JA, Henley KS. The role of serum biomarkers in hepatocellular carcinoma surveillance. Gastroenterol Hepatol, 2011,7:821-823.
  • 10Franco JR, Simarro PP, Diarra A, et al. The human African trypanosomiasis specimen biobank: a necessary tool to support research of new diagnostics. PLoS Negl Trop Dis, 2012,6:e1571.

共引文献90

同被引文献42

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部